{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.82","upperLimit":"0.95","value":"0.88"},{"groupId":"OG001","lowerLimit":"0.75","upperLimit":"0.90","value":"0.82"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"description":"Probability of no relapse, secondary malignancy, or death after 4 year in the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"Lung mets \\<= 1cm","id":"OG000","title":"Lung Mets <= 1cm"},{"description":"Lung mets \\> 1cm","id":"OG001","title":"Lung Mets > 1cm"}],"paramType":"NUMBER","populationDescription":"Analysis population is eligible stage (stg) IV patients (pts) with lung mets only. On Participant Flow table, these pts include 120 RCR, 135 SIR, 21 stg IV with LOH (of 52 when including stg III), and 23 stg IV with lung mets (off therapy before week 6). A total of 299 stg IV pts, exceeding the total number of participant (297) analyzed for OM 4.","reportingStatus":"POSTED","timeFrame":"At 4 years","title":"Event Free Survival Associated With the Burden of Pulmonary Metastatic Disease","type":"SECONDARY","unitOfMeasure":"Probability"}